Trials / Completed
CompletedNCT05067270
A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
A Study to Investigate Local Infusion Site Pain After Infusion of Excipients Across Infusion Sites and Infusion Depths
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to 36 days including a screening period and 3 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sodium Citrate | Administered SC infusion. |
| DRUG | Treprostinil | Administered SC infusion. |
| DRUG | Humalog diluent | Administered SC infusion. |
| DRUG | Magnesium Chloride | Administered SC infusion. |
Timeline
- Start date
- 2021-10-22
- Primary completion
- 2021-12-06
- Completion
- 2021-12-06
- First posted
- 2021-10-05
- Last updated
- 2023-10-04
- Results posted
- 2023-10-04
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT05067270. Inclusion in this directory is not an endorsement.